Nephrotic syndrome
Therapeutic area
Nephrology
Rare disease
No
- Definition
- A collection of symptoms that include severe edema, proteinuria, and hypoalbuminemia; it is indicative of renal dysfunction.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Nephrotic syndrome
- Therapeutic area
- Nephrology
- nephrotic syndrome
- nephrotic syndromes
- syndrome, nephrotic
- syndromes, nephrotic
- Disease mechanisms
- Syndromic
Sources for recorded values
- All therapeutic areas
- Nephrology
Sources for recorded values
- Severity
- Severe
- MONDO ID
- MONDO:0005377
- Parent condition
- MONDO:0002254
Related records
Broader conditions (7)
- Disease
- Disease by body system or component
- Human disease
- Kidney disorder
- Nephrosis
- Syndromic disease
- Urinary system disorder
Narrower conditions (48)
- Congenital nephrotic syndrome, Finnish type
- Familial idiopathic steroid-resistant nephrotic syndrome
- Familial idiopathic steroid-resistant nephrotic syndrome with diffuse mesangial proliferation
- Familial idiopathic steroid-resistant nephrotic syndrome with diffuse mesangial sclerosis
- Familial idiopathic steroid-resistant nephrotic syndrome with minimal changes
- Familial nephrotic syndrome
- Familial steroid-resistant nephrotic syndrome with sensorineural deafness
- Focal segmental glomerulosclerosis 1
- Idiopathic multidrug-resistant nephrotic syndrome
- Idiopathic nephrotic syndrome
- Idiopathic steroid-resistant nephrotic syndrome with sensitivity to second-line immunosuppressive therapy
- Idiopathic steroid-sensitive nephrotic syndrome
- Idiopathic steroid-sensitive nephrotic syndrome with diffuse mesangial proliferation
- Idiopathic steroid-sensitive nephrotic syndrome with focal segmental hyalinosis
- Idiopathic steroid-sensitive nephrotic syndrome with minimal change
- Idiopathic steroid-sensitive nephrotic syndrome with secondary steroid resistance
- Immunoglobulin-mediated membranoproliferative glomerulonephritis
- LAMB2-related infantile-onset nephrotic syndrome
- Nephrotic syndrome 14
- Nephrotic syndrome 15
Trials (196)
- A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases
- A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
- A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
- A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)
- A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome
- A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines
- A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence
- A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
- A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome
- A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
- Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
- Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
- ACTHAR Gel for Drug REsistant Nephrotic Syndrome in Children
- Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy
- Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome
- Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)
- Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
- Amiloride in Nephrotic Syndrome
- An Outcome Analysis of Primary Membranous Nephropathy
Approved drugs (20)
- Albumin human
- Betamethasone acetate
- Bumetanide
- Chlorothiazide
- Chlorothiazide sodium
- Chlorthalidone
- Cholestyramine
- Cortisone acetate
- Cyclophosphamide
- Dexamethasone
- Dexamethasone sodium phosphate
- Ethacrynic acid
- Furosemide
- Hydrochlorothiazide
- Methylprednisolone acetate
- Prednisolone
- Prednisolone sodium phosphate
- Prednisone
- Spironolactone
- Triamterene
Drugs in development (34)
- Abatacept Phase 2
- Acloproxalap Phase 2
- Aldesleukin Phase 2
- Alirocumab Phase 2
- Amiloride Phase 3
- Apixaban Phase 1
- Atorvastatin Phase 2
- Azithromycin Phase 1
- Azithromycin monohydrate Phase 1
- Belimumab Phase 2
- Corticotropin Phase 3
- Dalteparin sodium Phase 1
- Daratumumab Phase 2
- Dupilumab Phase 2
- Enoxaparin sodium Phase 2
- Felzartamab Phase 2
- Ilacirnon Phase 2
- Levamisole hydrochloride Phase 3
- Methylprednisolone Phase 3
- Mizoribine Phase 3
Other linked drugs (9)
- Betamethasone
- Betamethasone sodium phosphate
- Edoxaban
- Galactose
- Hydrocortisone
- Montelukast
- Triamcinolone
- Zinc acetate
- Zinc sulfate